Login
Therapeutic Area
Metabolic
Cardiovascular
Respiratory
Oncology
Products
All products
Metabolic
Jardiance
Synjardy
Heart Failure
Cardiovascular
Actilyse
Respiratory
OFEV
Oncology
Resources
ELEARNING
Login
Efficacy
Efficacy
Experience over four years
A nightmare called Exacerbations
Slow Progression PF-ILD
SSc-ILD: From Skin to lung. The Scencis implications
Expanding the ability to treat
Treatment & Diagnosis
Treatment & Diagnosis
IPF prevalence and diagnosis challenges
When it is more than a cough 1
When it is more than a cough 2
When it is more than a cough 3
Product information
Beyond FVC
Beyond FVC
Life is worth Living 1
Life is worth living 2
Life is worth Living 3
A nightmare called Exacerbations
Exacerbation Risk
Acute exacerbation of ILD is a deadly threat
Disease State
Disease State
Who to treat?
Abroad patient base
ILD Progression across CTD patients
PF is a common enemy (Pulmos 2)
Recognise and diagnose
IPF
Antifibrotic treatment
Guidelines
Confidence in Numbers
Confidence in Numbers
Clinical experience across multiple trials
A broad range of SSc-ILD patients
A common threat to SSc and CTD patients
Progression waits for no one
Clinical experience across multiple trials (Pulmos 2)
Wide Range of ILDs
Wide Range of ILDs
Risk of progression
OFEV
®
(nintedanib)
time to face
IPF head on
Efficacy
MPR-PH-100057
Production date: April 2021
Close
×
